Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality not only among the general population, but also in patients with chronic kidney disease (CKD). Several clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are gaining widespread acceptance as a principal therapy for the primary and secondary prevention of atherosclerosis and CVD.

Lipid and Blood Pressure
Meta-analysis Collaboration Group
Zeromskiego 113
90-549 Lodz, Poland
Phone/Fax: +48 42 639 37 71
© 2019 LBPMC. All rights reserved.